History
The pituitary gland is a small organ that is something like "the body's hormone command center," coordinating many functions at once, such as those of the thyroid, adrenal glands, gonads (ovaries/testes), growth, and water balance. Therefore, when a problem occurs in the pituitary gland, it is not just one specific organ that is affected; the balance of the whole body is disturbed, and various symptoms can appear all at once. In early medicine, these symptoms appeared to be separate diseases, and it was difficult to connect them to the fact that the cause was the pituitary gland.
Historically, the concept of pituitary disorders has developed along three lines: "hormone excess," "hormone deficiency," and "compression by a tumor." Diseases in which the face, hands, and feet become enlarged, such as gigantism and acromegaly; diseases in which weight increases and blood pressure and blood sugar rise, such as Cushing disease; and diseases in which milk secretion increases or menstruation stops were for a time recorded as different diseases, but gradually the common feature emerged that they arise when the pituitary gland secretes a particular hormone excessively. Conversely, forms in which hormones become deficient overall were also described, such as cases in which, after massive bleeding following childbirth, milk does not come in and lethargy and low blood pressure develop.
Advances in imaging tests changed the history of pituitary disorders. In the past, it was difficult to identify small tumors deep in the brain that could not be seen with the eye, but as magnetic resonance imaging became widespread, even small tumors became easier to find. In this process, "incidentally discovered pituitary tumors (incidentalomas)" increased, and criteria were developed to distinguish cases that need treatment from those that can be observed.
Surgery has also changed greatly. As surgery that removes the tumor by approaching through the nose without opening the brain widely became the standard, safety and outcomes improved. Recent research has summarized that rather than viewing pituitary tumors simply as "benign tumors," some tend to grow invasively or recur, so precise classification and tailored treatment are important.
Causes
The causes of pituitary disorders are easy to organize if understood in three broad categories. The first is a "mass (lesion)" such as a tumor or cyst arising in the pituitary gland itself. If this mass secretes a specific hormone excessively, a hormone excess syndrome develops, and if the mass grows or presses on normal tissue so that function declines, hormone deficiency develops. If the mass presses on the optic chiasm above it, a problem of narrowing of the visual field can also develop.
The second is inflammation and autoimmunity. Hypophysitis, in which the pituitary gland swells and loses function due to immune attack, belongs here. Forms associated with pregnancy and childbirth have been reported, and forms that can occur with certain systemic inflammatory diseases or infections, or after immunotherapy drugs used in cancer treatment, are also known. Even after the inflammation passes, hormone deficiency can remain if the pituitary tissue has been damaged.
The third is injury such as bleeding, impaired blood flow, or trauma. A representative example is pituitary apoplexy, in which bleeding or necrosis suddenly occurs within a pituitary tumor, which can create an emergency. In addition, Sheehan syndrome, in which the pituitary gland is damaged by massive bleeding during childbirth, and cases in which function declines after severe head trauma, brain surgery, or radiation therapy are also causes.
In addition, rarely, genetic diseases can raise the risk of pituitary tumors or hormone abnormalities, and there are also cases in which tumors from other sites metastasize or diseases of surrounding structures interfere with pituitary function. Recent research has summarized that in adults, pituitary tumors and their treatment account for a large share of hormone deficiency, while in children, congenital developmental abnormalities and genetic factors are relatively more important.
Genetic Epidemiology
Most pituitary disorders occur without a family history, but in some, a genetic background is involved. Typically, in certain genetic syndromes, the risk of developing pituitary tumors increases. In such cases, a person may have not only a pituitary tumor but also tumors in other endocrine organs (parathyroid, pancreas, etc.), so family-based evaluation becomes necessary.
Another form is a case in which "only pituitary tumors" recur within a family, such as familial pituitary adenoma. In such families, tumors may develop at a relatively young age or grow large, so early detection becomes more meaningful. However, these hereditary forms account for only a small portion of all pituitary tumors, and most people are approached through the standard diagnostic and treatment pathway without genetic testing. Genetic factors may also exist in hormone deficiency (hypopituitarism). In children, gene variants related to pituitary development can present as a form in which several hormones are deficient together, and growth delay or delayed puberty is a clue.
An important point in understanding genetic epidemiology is that "genetics is not destiny." Even with the same genetic variant, not everyone may develop the disease, and environmental and other factors may act together. Therefore, in actual clinical practice, the need for genetic evaluation is judged by considering family history, age at onset, tumor type, and coexisting diseases together.
General Epidemiology
The most common category of pituitary disorders is pituitary tumors. They are relatively common even among tumors in the brain, and some cause almost no symptoms and are discovered incidentally during imaging tests. On the other hand, clinically problematic cases present as systemic symptoms due to hormone excess, problems such as chronic fatigue, low blood pressure, and decreased sexual function due to hormone deficiency, or compression symptoms such as visual disturbances and headache.
Hypopituitarism is relatively rare but is easily underdiagnosed. When hormones decrease gradually, it begins with nonspecific symptoms such as fatigue, weight changes, depressed mood, and decreased libido and can be mistaken for other diseases. Recent research has suggested the possibility that factors such as head trauma, aftereffects of brain tumor treatment, and the increasing use of immunotherapy drugs are changing the epidemiology of hypopituitarism. Pituitary apoplexy is low in frequency but is an important epidemiological event. It usually occurs suddenly in people who already have a pituitary tumor, and there are reports that it is relatively more common in middle-aged men.
Overall, pituitary disorders are not "a few rare diseases" but have a broad spectrum ranging from common incidentalomas to emergencies. Therefore, when understanding the epidemiology, it is more realistic to look not at a single number but at which disease groups (hormone excess, hormone deficiency, inflammation, apoplexy) can increase or decrease in which settings.
Pathogenesis
The pathogenesis of pituitary disorders can be summarized as "how the hormone-producing cells break down or how they overwork." In neoplastic diseases, pituitary cells grow to form a mass, and that mass autonomously secretes a specific hormone. For example, excess growth hormone causes acromegaly, excess adrenocorticotropic hormone causes Cushing disease, and excess prolactin causes problems such as menstrual abnormalities and increased milk secretion. Even if a tumor does not produce hormones, as it grows it can press on the normal pituitary gland, causing deficiency of several hormones.
There are two main mechanisms of hormone deficiency. One is when the pituitary gland is damaged and cannot produce hormones, and the other is when the hypothalamus, which controls the pituitary gland, or the pituitary stalk (the connecting part) is damaged so that "command signals" are not transmitted. In the latter case, prolactin may paradoxically rise, because the inhibitory signal that normally comes down from the hypothalamus is cut off. In inflammatory diseases, immune cells attack the pituitary gland, causing it to swell and lose function. In this case, a mass that looks like a tumor may form, so it can be difficult to distinguish on imaging alone.
The mechanism of pituitary apoplexy is abrupt. As tissue becomes necrotic due to bleeding within the tumor or blockage of blood flow, its volume suddenly increases, causing headache, visual disturbances, and decreased consciousness. At the same time, if the adrenocorticotropic hormone axis suddenly drops, it can lead to low blood pressure and shock, so immediate steroid replacement is important.
Recent research has summarized that the "molecular characteristics" and microenvironment (immune cells, inflammatory signals) of tumors may be associated with invasive and recurrent tendencies. This may lead in the long term to prognostic prediction and the development of targeted therapies.
Symptoms
The symptoms of pituitary disorders are very diverse, but they become easier to understand if divided into three broad branches: "hormone excess," "hormone deficiency," and "compression." In hormone excess, the functions governed by the hormone concerned are exaggerated. Excess growth hormone can cause changes in facial contours, enlargement of the hands and feet, joint pain, increased sweating, and worsening of hypertension and diabetes. Excess adrenocorticotropic hormone can cause weight gain, obesity centered on the face and trunk, thinning of the skin and bruising, muscle weakness, elevated blood pressure and blood sugar, and susceptibility to infection. Excess prolactin can cause irregular menstruation or amenorrhea and milk secretion in women, and decreased libido and erectile problems in men.
Conversely, in hormone deficiency, energy drops and "the body slows down." Deficiency of thyroid-stimulating hormone can cause sensitivity to cold, lethargy, and constipation, and deficiency of adrenocorticotropic hormone can cause severe fatigue, loss of appetite, low blood pressure, and dizziness. Gonadotropin deficiency can lead to infertility, decreased libido, and an increased risk of osteoporosis. Antidiuretic hormone deficiency presents as drinking a lot of water and passing excessive amounts of urine.
Compression symptoms become prominent as the tumor grows. Neurological symptoms such as headache, a feeling that the visual field is narrowing from both sides, and double vision (diplopia, seeing objects as two) can develop. When pituitary apoplexy occurs, sudden severe headache, nausea and vomiting, decreased vision, and changes in consciousness can appear rapidly.
Recent research has emphasized that symptoms patients experience only as "simple fatigue" or "depressed mood" may actually be signals of a hormone problem, so it is important not to dismiss nonspecific symptoms lightly.
Signs
The signs confirmed on examination and testing also correspond to the classification of symptoms. In hormone excess, objective findings such as characteristic changes in body shape or skin, abnormal blood pressure and blood sugar, specific changes in facial contours, and milk discharge (galactorrhea) are clues. In hormone deficiency, findings of low blood pressure, weight changes, a tendency toward anemia, decreased bone density, and low sex hormones may appear.
Signs related to the eyes are especially important. Because the pituitary gland lies just below the optic chiasm, as a tumor grows, visual field defects in which the outer visual fields on both sides are reduced can develop. The person may feel this only as "I can't see well to the side," but it is clearly confirmed on visual field testing.
In pituitary apoplexy, neurological signs can appear at an emergency level. Drooping eyelids, impaired eye movement, a sharp drop in vision, and decreased consciousness can occur, and hyponatremia may also appear on blood tests. Above all, if adrenal insufficiency is present, blood pressure can drop sharply, so it is important to decide to start treatment first if it is clinically suspected, rather than waiting for test results.
In inflammatory pituitary disease, findings on imaging such as overall swelling of the pituitary gland and a thickened-appearing pituitary stalk are clues, but there are cases in which it is difficult to distinguish from a tumor. Recent research has summarized that looking at imaging patterns together with the clinical context (pregnancy, use of immunotherapy drugs, etc.) can help reduce unnecessary surgery.
Screening
Pituitary disorders are not diseases for which broad screening tests are performed on the asymptomatic general population. Instead, screening is done with "hormone evaluation + imaging tests" when certain signals are present. Representative situations requiring screening are as follows. First, when there is a visual disturbance of unknown cause or persistent headache, especially with a feeling that the visual fields on both sides are narrowing. Second, when an abnormality of the sex hormone axis is suspected, such as increased milk secretion, cessation of menstruation, decreased libido or erectile problems, or infertility. Third, when excess of a specific hormone is suspected, such as changes in the face, hands, and feet, weight gain and skin changes, or worsening of hypertension and diabetes. Fourth, when adrenal insufficiency is suspected because of accompanying severe fatigue, low blood pressure, and weight loss.
Basic screening begins with blood tests. Because the pituitary gland affects several hormone axes, a structure is needed in which, rather than looking at only one value, the related end-organ hormones (thyroid hormone, cortisol, sex hormones, etc.) and pituitary hormones are looked at together. In some cases, additional tests called "stimulation tests" are needed. For imaging, pituitary magnetic resonance imaging is the standard. If there are vision problems, visual field testing is done at the same time.
Recent research has discussed that, as incidentalomas increase, an approach of setting follow-up intervals based on "size, distance from the optic nerve, and presence of hormone abnormalities" has become important. It is realistic to use screening tests in a targeted way, focusing on cases with symptoms or identified risk factors.
Diagnosis
Diagnosis is easy to organize if thought of in three stages. Stage 1 is forming a hypothesis about which axis is the problem based on the clinical presentation. Stage 2 is using blood tests to confirm whether it is hormone excess or deficiency and which axis has been disrupted. Stage 3 is using magnetic resonance imaging to confirm whether the cause is a tumor, inflammation, bleeding, or a problem with surrounding structures.
In hormone excess diseases, "the oversecreted hormone + the indicators that increase in the end organs as a result" are checked together, and it is distinguished whether the cause is the pituitary gland (excessive secretion from the pituitary) or an end organ (adrenal gland, thyroid, etc.). In hormone deficiency, a pattern in which the end-organ hormones are low but the pituitary hormones do not rise appropriately is a clue. In diagnosing hypopituitarism, the adrenal axis is especially important. Cortisol deficiency can become life-threatening, so it must be checked first. In addition, the order of hormone replacement is important; raising thyroid hormone first without first replacing adrenal hormones can be dangerous, so diagnosis and treatment must be designed together.
When there are causes other than a tumor, such as inflammatory disease or pituitary apoplexy, imaging findings and the clinical context are important. In some cases, a biopsy helps confirm the diagnosis, but it is not always necessary, and the decision is made by weighing risks and benefits.
Recent research has emphasized that because the sensitivity of test methods and the limits of their interpretation, as well as interactions between multiple hormone replacement therapies, can affect patient outcomes, a multidisciplinary approach is important.
Treatment
There are three treatment goals. First, to immediately correct life-threatening hormone deficiencies (especially of adrenal hormones). Second, to treat the cause, such as a tumor or inflammation, or reduce its size to relieve compression. Third, to balance hormones over the long term and monitor for recurrence.
Tumor treatment combines surgery, medication, and radiation therapy. For tumors that do not produce hormones or that cause significant compression, surgery is usually central. For prolactin-excess tumors, drug therapy is often the first line. For growth hormone excess or Cushing disease, surgery comes first, but if surgery is difficult or tumor remains, drug therapy may be used in combination. Recent research has summarized that as drug therapy options increase and surgical techniques and radiation therapy methods become more refined, individualized strategies have become important.
For hypopituitarism, "hormone replacement" is key. The deficient hormones are replaced in amounts close to what the body would originally have produced. The dose is adjusted in consideration of lifestyle patterns, other diseases, pregnancy plans, infection risk, and so on, and it is reassessed regularly. For inflammatory pituitary disease, immunomodulatory treatment such as steroids can be helpful, and if compression of the optic nerve is severe, surgical decompression may be needed.
Pituitary apoplexy is an emergency. Intravenous steroids are given immediately along with correction of fluids and electrolytes, and if there is deterioration in vision or neurological status, prompt surgery is considered. Recent research has discussed that some patients can have a good course even with conservative treatment, so choosing treatment according to the patient's condition is important.
Prognosis
The prognosis depends greatly on the cause and the timing of treatment. Small incidentalomas often never cause problems throughout life and require only observation. Conversely, hormone-excess tumors can increase the risk of complications such as cardiovascular disease, diabetes, and osteoporosis if left untreated, so early treatment is important. The prognosis after surgery varies depending on the tumor size and degree of invasion, the type of hormone, and surgical experience. Cure is sometimes possible, but there are also cases in which recurrence or residual tumor requires additional treatment.
Hypopituitarism often does not recover completely even when the cause is resolved, so long-term hormone replacement may be needed. However, appropriate replacement therapy can greatly improve quality of life. That said, for people with adrenal insufficiency, the concept of a "stress dose," in which the dose must be increased during infection, surgery, or major stress, is important, and not knowing this can be dangerous.
In pituitary apoplexy, visual field and eye movement impairments often improve after treatment, but hormone deficiency commonly remains. Recent research has emphasized that some pituitary tumors show invasive and recurrent tendencies, requiring long-term follow-up, and results have also been presented suggesting that differences in hormone recovery between conservative treatment and surgical treatment may not be clear.
Prevention
There are not many definite ways to completely prevent pituitary disorders. However, there are several realistic prevention strategies. First, "early detection" is the most powerful prevention. Because hormone excess or deficiency appears early with nonspecific symptoms (fatigue, weight changes, depressed mood, decreased sexual function), considering hormone testing when symptoms persist for a long time or symptoms of several axes overlap helps prevent complications.
Second, secondary prevention in people already diagnosed is important. People with tumors should be followed with magnetic resonance imaging and hormone tests at set intervals to catch recurrence and loss of function early. People who have had vision problems should also have visual field testing. Third, for people receiving hormone replacement therapy, education about crisis situations is prevention. In particular, with adrenal insufficiency, failing to increase the steroid dose in situations such as high fever, vomiting, or surgery can be dangerous, so crisis response should be prepared through an emergency card and education.
Fourth, for people with large tumors at risk of pituitary apoplexy, it is important to know the triggering factors (use of anticoagulants, major surgery, sudden changes in blood pressure, etc.) and warning symptoms (sudden severe headache, decreased vision) and to seek medical care quickly.
Recent research continues to clarify guidelines for managing incidentalomas, follow-up intervals, and the relationship between everyday risk factors and prognosis, so future prevention strategies are likely to develop toward "precise follow-up and tailored risk management."